Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression

Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Eun Hee Choi; Jae Yeon Seok; Jung Min Lee; Young Nyun Park; Chae Yoon Chon; Kwang Hyub Han

doi:10.1007/s12072-010-9201-7

Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression

Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Eun Hee Choi, Jae Yeon Seok, Jung Min Lee, Young Nyun Park, Chae Yoon Chon, Kwang Hyub Han

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Background: Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. Methods: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. Results: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). Conclusions: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.

Original language	English
Pages (from-to)	673-680
Number of pages	8
Journal	Hepatology International
Volume	4
Issue number	4
DOIs	https://doi.org/10.1007/s12072-010-9201-7
Publication status	Published - 2010 Dec

Bibliographical note

Funding Information:
Acknowledgements This study was supported by the Grant of the Good Health R&D Project from the Ministry of Health, Welfare and Family Affairs, Republic of Korea (A050021), and in part by Brain Korea 21 Project for Medical Science. The authors wish to thank Joon Seong Kim, Ji Won Kim and Jeong Min Cho for their critical comments and support.

All Science Journal Classification (ASJC) codes

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-010-9201-7

Cite this

Kim, S. U., Park, J. Y., Kim, D. Y., Ahn, S. H., Choi, E. H., Seok, J. Y., Lee, J. M., Park, Y. N., Chon, C. Y., & Han, K. H. (2010). Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression. Hepatology International, 4(4), 673-680. https://doi.org/10.1007/s12072-010-9201-7

@article{abf689d0605e497487a2502ff7edfa69,

title = "Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression",

abstract = "Background: Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. Methods: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. Results: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). Conclusions: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.",

author = "Kim, {Seung Up} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Choi, {Eun Hee} and Seok, {Jae Yeon} and Lee, {Jung Min} and Park, {Young Nyun} and Chon, {Chae Yoon} and Han, {Kwang Hyub}",

note = "Funding Information: Acknowledgements This study was supported by the Grant of the Good Health R&D Project from the Ministry of Health, Welfare and Family Affairs, Republic of Korea (A050021), and in part by Brain Korea 21 Project for Medical Science. The authors wish to thank Joon Seong Kim, Ji Won Kim and Jeong Min Cho for their critical comments and support.",

year = "2010",

month = dec,

doi = "10.1007/s12072-010-9201-7",

language = "English",

volume = "4",

pages = "673--680",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "4",

}

Kim, SU , Park, JY , Kim, DY , Ahn, SH, Choi, EH, Seok, JY, Lee, JM, Park, YN, Chon, CY & Han, KH 2010, 'Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression', Hepatology International, vol. 4, no. 4, pp. 673-680. https://doi.org/10.1007/s12072-010-9201-7

TY - JOUR

T1 - Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B

T2 - Impact of antiviral treatment on fibrosis regression

AU - Kim, Seung Up

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Choi, Eun Hee

AU - Seok, Jae Yeon

AU - Lee, Jung Min

AU - Park, Young Nyun

AU - Chon, Chae Yoon

AU - Han, Kwang Hyub

N1 - Funding Information: Acknowledgements This study was supported by the Grant of the Good Health R&D Project from the Ministry of Health, Welfare and Family Affairs, Republic of Korea (A050021), and in part by Brain Korea 21 Project for Medical Science. The authors wish to thank Joon Seong Kim, Ji Won Kim and Jeong Min Cho for their critical comments and support.

PY - 2010/12

Y1 - 2010/12

N2 - Background: Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. Methods: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. Results: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). Conclusions: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.

AB - Background: Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. Methods: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. Results: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). Conclusions: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.

UR - http://www.scopus.com/inward/record.url?scp=78649454371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649454371&partnerID=8YFLogxK

U2 - 10.1007/s12072-010-9201-7

DO - 10.1007/s12072-010-9201-7

M3 - Article

C2 - 21286337

AN - SCOPUS:78649454371

SN - 1936-0533

VL - 4

SP - 673

EP - 680

JO - Hepatology International

JF - Hepatology International

IS - 4

ER -

Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: Impact of antiviral treatment on fibrosis regression

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this